Peer-reviewed veterinary case report
Blocking survivin protein to treat canine lymphoma and bone cancer
By Shoeneman, J. K. et al.·Published in Veterinary and Comparative Oncology·2014·Flint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences Colorado State University Fort Collins CO USA, United States·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Survivin inhibition via EZN‐3042 in canine lymphoma and osteosarcoma
- Species:
- dog
Plain-English summary
A study found that dogs with lymphoma or osteosarcoma (a type of bone cancer) often have high levels of a protein called survivin, which helps cancer cells survive and grow. Researchers tested a treatment called EZN-3042, which targets survivin, and discovered that it could slow down cancer growth and make cancer cells more sensitive to chemotherapy. This suggests that EZN-3042 might be a promising new option for treating dogs with these serious cancers. Further evaluation in dogs with cancer is recommended to see how well this treatment works in real-life situations.
People also search for: dog lymphoma treatment · osteosarcoma in dogs · EZN-3042 for canine cancer · dog cancer survival rates · canine cancer therapies
Abstract
AbstractCanine lymphoma (LSA) and osteosarcoma (OS) have high mortality rates and remain in need of more effective therapeutic approaches. Survivin, an inhibitor of apoptosis (IAP) family member protein that inhibits apoptosis and drives cell proliferation, is commonly elevated in human and canine cancer. Survivin expression is a negative prognostic factor in dogs with LSA and OS, and canine LSA and OS cell lines express high levels of survivin. In this study, we demonstrate that survivin downregulation in canine LSA and OS cells using a clinically applicable locked nucleic acid antisense oligonucleotide (EZN‐3042, Enzon Pharmaceuticals, Piscataway Township, NJ, USA) inhibits growth, induces apoptosis and enhances chemosensitivity in vitro, and inhibits survivin transcription and protein production in orthotopic canine OS xenografts. Our findings strongly suggest that survivin‐directed therapies might be effective in treatment of canine LSA and OS and support evaluation of EZN‐3042 in dogs with cancer.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1111/vco.12104